Characterization of the biological and molecular activity of PML in breast cancer

  1. Arreal López, Leire
Dirigée par:
  1. Arkaitz Carracedo Pérez Directeur/trice
  2. Natalia Martin Martin Directeur/trice

Université de défendre: Universidad del País Vasco - Euskal Herriko Unibertsitatea

Fecha de defensa: 23 novembre 2020

Jury:
  1. Ana María Zubiaga Elordieta President
  2. Manuel Collado Rodríguez Secrétaire
  3. Rosa Bernardi Rapporteur
Département:
  1. Bioquímica y Biología Molecular

Type: Thèses

Teseo: 153085 DIALNET lock_openADDI editor

Résumé

Oncogene addiction postulates that the survival and growth of certain tumor cells is dependent upon the activity of one oncogene, despite their multiple genetic and epigenetic abnormalities. This phenomenon provides a foundation for molecular targeted therapy and a rationale for oncogene-based stratification. We previously reported that the Promyelocytic Leukemia protein (PML) is upregulated in triple negative breast cancer (TNBC) and it regulates cancer-initiating cell function, thus suggesting that this protein can be therapeutically targeted in combination with PML-based stratification. However, the effects of PML perturbation on the bulk of tumor cells remained poorly understood. In this thesis work we demonstrated that TNBC cells are addicted to the expression of this nuclear protein. PML inhibition led to a remarkable growth arrest combined with features of senescence in vitro and in vivo. Mechanistically, we observed that growth arrest and senescence were associated to a decrease in MYC and PIM1 kinase levels, with the subsequent accumulation of cyclin-dependent kinase inhibitor 1B (CDKN1B, p27), a trigger of senescence. In line with this notion, we found that PML is associated to thepromoter regions of MYC and PIM1, consistent with their direct correlation in breast cancer specimens. Altogether, our results provide a feasible explanation for the functional similarities of MYC, PIM1, and PML in TNBC and encourage further study of PML targeting strategies for the treatment of this breast cancer subtype.